Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: SomaKit TOC (edotreotide) — Novartis Europharm Limited
EMA authorised SomaKit TOC (edotreotide) for neuroendocrine tumors and radionuclide imaging; orphan medicine status.
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Results: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]
Phase 2 trial results for nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lun…
-
EMA approval · 2026-08-14EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Novartis Europharm Limited
Lutetium-177 Lu oxodotreotide (Lutathera) has been authorised by EMA for neuroendocrine tumors, designated as an orphan medicine.
-
EMA approval · 2026-07-21EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Novartis Europharm Limited
EMA authorised Lutathera (lutetium-177 Lu oxodotreotide) for neuroendocrine tumors; orphan medicine designation.
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas [Phase 2, Phase 3]
A Phase 2/Phase 3 trial evaluating Sandostatin LAR plus Axitinib versus placebo in patients with advanced well-differentiated non-pancreatic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Results: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas [Phase 2, Phase 3]
A completed phase 2/3 trial evaluating Sandostatin LAR plus axitinib versus placebo in patients with advanced well-differentiated non-pancre…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer [Phase 2]
Phase 2 clinical trial evaluating autologous T cells engineered to express T-cell receptors against neoantigens in metastatic cancer, curren…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma [Phase 2]
A Phase 2 clinical trial evaluating Lutathera (Lutetium-177 DOTATATE) for inoperable pheochromocytoma and paraganglioma is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Ultralow Dose PET Imaging of 18F-FDOPA [Phase 2]
Phase 2 trial evaluating ultralow-dose PET imaging with the radiotracer 18F-FDOPA in healthy volunteers and Parkinsonian syndromes to assess…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer [Phase 1, Phase 2]
A dose-defining study of tirapazamine combined with embolization in liver cancer (hepatocellular carcinoma) is in Phase 1/Phase 2 and curren…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Agnostic Therapy in Rare Solid Tumors [Phase 2]
A Phase 2 trial of an agnostic therapy for multiple rare solid tumors is currently recruiting. The study lists a broad set of tumor types ac…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours [Phase 1]
Phase 1 trial update evaluating the combination of 177Lu-DOTA-TATE with Olaparib in somatostatin receptor-positive tumors has completed. The…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Lutathera (177Lu-DOTATATE) in combination with Olaparib for somatostatin receptor–expressing recurrent…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients [Phase 3]
Phase 3 trial update evaluating the efficacy and safety of 177Lu-edotreotide peptide receptor radionuclide therapy in gastroenteropancreatic…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 [Phase 1]
Phase 1 study evaluating tolerability of different doses of Obrixtamig (BI 764532) in combination with Ezabenlimab in patients with small ce…
-
EMA approval · 2026-03-25EMA Authorised: SomaKit TOC (edotreotide) — Advanced Accelerator Applications
EMA authorised SomaKit TOC (edotreotide) for imaging neuroendocrine tumors; the product is designated an orphan medicine and is associated w…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation
This update describes a study evaluating circulating progastrin (hPG80) as a diagnostic biomarker for neuroendocrine tumors in patients with…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
A clinical trial entry indicates that a study evaluating peptide receptor radionuclide therapy for neuroendocrine tumors is currently recrui…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor
A real-world prospective cohort study in advanced neuroendocrine tumors evaluating survival without persistent limiting toxicity.
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Entinostat Neuroendocrine (NE) Tumor [Phase 2]
Phase 2 trial of entinostat in neuroendocrine tumors was terminated. Results were posted on 2026-03-02.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Combination Immunotherapy in Rare Cancers Under InvesTigation [Phase 2]
This is a Phase 2 trial update describing a combination immunotherapy study for rare cancers; the trial is currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer [Phase 2]
Phase 2 trial of pembrolizumab plus lenvatinib in advanced/metastatic neuroendocrine prostate cancer; results were posted in February 2026.
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: 18F-DOPA II - PET Imaging Optimization [Phase 3]
Phase 3 trial of the imaging agent 18F-DOPA II for PET imaging optimization is currently recruiting, sponsored by the University of Alberta,…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department [NA]
Clinical trial update describing a clinico-biological database for patients treated with metabolic radiotherapy in the Nuclear Medicine depa…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: F-Tryptophan PET/CT in Human Cancers [Phase 1]
A Phase 1 study evaluating F-Tryptophan PET/CT imaging across several cancers (intracranial glioma, metastatic brain tumor, breast cancer, n…